Articles tagged "HLA antibodies"

2022 American Transplant Congress
Characterizing the Landscape of Cancer Risk Following HLA-Incompatible Living Donor Kidney Transplantation
J. D. Motter¹, K. Jackson¹, K. Yu², R. M. Pfeiffer², A. Massie¹, J. Garonzik-Wang³, D. Segev¹, E. A. Engels²
¹Johns Hopkins University, Baltimore, MD, ²National Cancer Institute, Bethesda, MD, ³University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
2022 American Transplant Congress
Outcomes of Highly-Sensitized, Virtual and Flow Cross-Match Negative Renal Transplant Recipients: A Retrospective Observational Study
A. Agrawal¹, B. Smith¹, M. Gandhi², C. Schinstock¹
¹Transplant Nephrology, Mayo Clinic, Rochester, MN, ²Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
*Purpose: Many highly-sensitized kidney transplant recipients are sensitized from prior transplants, which have been shown to limit graft survival more than pregnancy or blood transfusions.…
2022 American Transplant Congress
Prolonged Xeno-Kidney Graft Survival in Highly Allo-Sensitized Nonhuman Primate Using Triple-Knockout Donor Pigs with 7 Human Transgenes
M. Manook¹, D. Olaso¹, I. Anwar¹, J. Yoon¹, M. Song¹, A. B. Farris², K. Stiede³, K. Hall³, M. Youd³, S. Knechtle¹, J. Kwun¹
¹Surgery, Duke Transplant Center, Durham, NC, ²Pathology, Emory University, Atlanta, GA, ³eGenesis Inc, Cambridge, MA
*Purpose: We have previously shown using porcine kidneys from genetically modified knockout alpha 1,3-galactosyltransferase (GGTA1KO) and human decay accelerating factor transgenic (CD55Tg) pigs that compared…
2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
K. Progar¹, K. Kurwicki², N. Nesselhauf³, J. Hagopian⁴, S. January⁵, H. Wijeweera⁶, M. McCloskey⁷, M. Merzkani⁸, R. Delos Santos⁹
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²SSM Health Saint Louis University Hospital, Saint Louis, MO, ³Barnes-Jewish Hospital, Edwardsville, IL, ⁴Pharmacy, University of Michigan, Ann Arbor, MI, ⁵Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ⁶Washington University, Saint Louis, MO, ⁷Barnes-Jewish Hospital, St. Louis, MO, ⁸Washington University, St Louis, MO, ⁹Transplant, Washington University, St. Louis, MO
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…
2022 American Transplant Congress
HLA DSA May Not Be Detected in Many Solid Organ Recipients
J. C. Quon¹, R. M. Lestz², J. Menteer², N. Fotiadis², L. A. Baxter-Lowe²
¹Keck School of Medicine, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
*Purpose: Clinically significant HLA antibodies may not be detected if their unique HLA epitopes are not represented in the single antigen reagents that are routinely…
2022 American Transplant Congress
Local Intragraft Humoral Immune Response in Chronic Lung Allograft Dysfunction
E. Miyamoto¹, S. C. Juvet², D. Vosoughi², J. Wang², J. Al-Refaee², T. Daigneault², A. Duong², S. Moshkelgosha², S. Keshavjee², K. Tinckam², A. Chruscinski³, D. Hwang⁴, T. Martinu²
¹Tenri Hospital Japan, University Health Network Canada, Nara, Japan, ²University Health Network, Toronto, ON, Canada, ³Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, ⁴Sunnybrook Health Science Centre, Toronto, ON, Canada
*Purpose: Donor HLA-specific antibody (DSA) and antibody against self-antigens (self-antigen antibody) can cause injury and lead to chronic lung allograft dysfunction (CLAD) after lung transplantation…
2022 American Transplant Congress
Which is More Important for Predicting De Novo DSA Production, B Cell Epitope (EPLET) or T Cell Epitope (PIRCHE) Analysis ?
T. Kobayashi¹, T. Tomosugi², S. Sakamoto², S. Ashimine¹, K. Iwasaki¹, M. Niemann³, E. Spierings⁴, Y. Miwa¹, M. Okumura¹, K. Ishiyama¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³PIRCHE AG, Berlin, Germany, ⁴UMC Utrecht, Utrecht, Netherlands
*Purpose: De novo donor-specific antibodies (dnDSA) can cause chronic ABMR, resulting in poor prognosis. Recently, mismatch at B cell epitope level, i.e. EPLET mismatch, has…
2022 American Transplant Congress
Early Clinical Complications Following HLA-Incompatible Living Donor Kidney Transplantation
J. D. Motter¹, K. Jackson¹, A. Massie¹, J. Garonzik-Wang², D. Segev¹
¹Johns Hopkins University, Baltimore, MD, ²University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
2022 American Transplant Congress
Three-Way Comparison of Central DSA, %dd-cf DNA, and Molecular Biopsy Findings in the Trifecta Study
P. F. Halloran¹, L. G. Hidalgo², Z. Demko³, A. Prewett³, J. Reeve¹, C. Lawrence⁴, D. Lowe⁴, P. Billings³, .. and the Trifecta Investigators⁵
¹Alberta Transplant Applied Genomics Centre, Edmonton AB, AB, Canada, ²University of Wisconsin, Madison, WI, ³Natera Inc., San Carlos, CA, ⁴One Lambda Inc., West Hills, CA, ⁵., ., AB, Canada
*Purpose: Trifecta (ClinicalTrials.gov #NCT04239703) is a prospective, IRB-approved, consented study of the relationships among three central tests in kidney transplant indication biopsies: molecular biopsy diagnoses…
2022 American Transplant Congress
Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up
A. Vo¹, J. Tang¹, N. Ammerman¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a cytokine critical for B-cell activation and IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6.…

1
2
3
…
47
Next Page »